SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-030107
Filing Date
2023-06-27
Accepted
2023-06-27 16:05:54
Documents
12
Period of Report
2023-06-27
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20230627.htm   iXBRL 8-K 55060
  Complete submission text file 0000950170-23-030107.txt   176723

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20230627_lab.xml EX-101.LAB 13904
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20230627.xsd EX-101.SCH 2466
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20230627_pre.xml EX-101.PRE 10228
6 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20230627_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 231047318
SIC: 2834 Pharmaceutical Preparations